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The natriuretic peptides (NP) consist of a group of
genetically distinct peptides with a 17 amino acid disul-
fide ring structure that exert important paracrine and
endocrine actions in cardiorenal homeostasis. ANP and
BNP bind to the natriuretic peptide-A receptor (NPR-A),
which via 3’,5’-cyclic guanosine monophosphate (cGMP)
mediates natriuresis, vasodilatation, renin-aldosterone
inhibition, anti-mitogenesis, and positive lusitropism.
CNP lacks natriuretic actions, but possesses vasodilating
and important growth- and fibrotic-inhibiting actions via
the guanylyl cyclase-linked natriuretic peptide-B receptor
(NPR-B). CD-NP now represents the first designer NP
which, unlike ANP, BNP or CNP, co-activates both NPR-
A and NPR-B.
In both experimental and human heart failure (HF),
investigations have supported the hypothesis that the
capacity of the cardiomyocytes to produce and/or release
the NP may be overwhelmed in HF due to the increased
demands of the system, thus leading to a state of relative
deficiency of biologically active endogenous NP. Hence,
giving the favorable cardiorenal and humoral proprieties
of the NP, their chronic exogenous delivery is now
viewed as favorable therapeutic opportunity for the treat-
ment of cardiovascular diseases.
We have previously reported that subcutaneous (SQ)
administration of BNP in experimental HF resulted in
improved cardiac output with reduced systemic vascular
resistance and cardiac filling pressures. Importantly, we
translated these studies to humans and completed a pilot
study to establish safety and efficacy of 8 weeks of chronic
SQ BNP administration in human symptomatic systolic
HF. More importantly, we have recently completed
2 proof of concept studies to assess the biological effects
of 12 weeks of SQ BNP administration in patients with
preclinical systolic dysfunction and patients with preclini-
cal diastolic dysfunction (Stage B HF). These studies
demonstrated that chronic SQ BNP induced a sustained
generation of cGMP, which, importantly, was associated
with persistent enhanced renal natriuretic response to
volume overload.
Going beyond BNP, CD-NP (Cenderitide) is in clinical
development as an outpatient therapy during the post-
acute HF period, to be administered continuously for up
to 90 days after hospital discharge via subcutaneous pump
with the goals of reducing rehospitalization. Recently, a
phase 1 study in HF patients was completed which
demonstrated that SQ CD-NP infusion achieved desirable
pharmacokinetic levels and was well tolerated. Pre-clini-
cally, we have recently designed an in situ polymer precipi-
tation delivery system suitable for the chronic and
sustained release of CD-NP. With the appropriate poly-
mer-gel formulation, CD-NP release could be sustained
over 3 weeks, thus inducing prolonged cGMP activation
and favourable biological actions.
Preclinical and early phase clinical studies have demon-
strated the potential beneficial actions of chronic NP ther-
apeutics. Further studies are warranted to determine if
these functional responses can be translated into improved
clinical outcomes and contribute to delaying the progres-
sion of HF.
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